Parkinson’s disease is the second most common neurological disease and affects about 1% of persons over the age of 60 years. Due to the lack of approved surrogate markers, confirmation of the disease still requires postmortem examination. Identifying and validating biomarkers are essential steps toward improving clinical diagnosis and accelerating the search for therapeutic drugs to ameliorate disease symptoms. Until recently, statistical analysis of multicohort longitudinal studies of neurodegenerative diseases has usually been restricted to a single analysis per outcome with simple comparisons between diagnostic groups. However, an important methodological consideration is to allow the modeling framework to handle multiple outcomes simultaneously and consider the transitions between diagnostic groups. This enables researchers to monitor multiple trajectories, correctly account for the correlation among biomarkers, and assess how these associations may jointly change over the long-term course of disease. In this study, we apply a latent time joint mixed-effects model to study biomarker progression and disease dynamics in the Parkinson’s Progression Markers Initiative (PPMI) and examine which markers might be most informative in the earliest phases of disease. The results reveal that, even though diagnostic category was not included in the model, it seems to accurately reflect the temporal ordering of the disease state consistent with diagnosis categorization at baseline. In addition, results indicated that the specific binding ratio on striatum and the total Unified Parkinson’s Disease Rating Scale (UPDRS) show high discriminability between disease stages. An extended latent time joint mixed-effects model with heterogeneous latent time variance also showed improvement in model fit in a simulation study and when applied to real data.

Keywords:
Biomarkers, Disease trajectories, Clinical diagnosis, Multilevel Bayesian models, Joint mixed-effects models, Latent time shift, Multicohort longitudinal data, Parkinson’s disease
1.
Kennedy RE, Cutter GR, Wang G, Schneider LS: Using baseline cognitive severity for enriching Alzheimer’s disease clinical trials: how does Mini-Mental State Examination predict rate of change? Alzheimers Dement (NY) 2015; 1: 46–52.
2.
Guerrero R, Schmidt-Richbergh A, Ledig C, Tong T, Wolz R, Rueckert D: Instantiated mixed effects modeling of Alzheimer’s disease markers. Neuroimage 2016; 142: 113–125.
3.
Sturkenboom IH, Graff MJ, Hendriks JC, Veenhuizen Y, Munneke M, Bloem BR, Sanden MW: Efficacy of occupational therapy for patients with Parkinson’s disease: a randomized controlled trial. Lancet Neurol 2014; 13: 557–566.
4.
Klotsche J, Reese JP, Winter Y, Oertel WH, Irving H, Wittchen H, Rehm J, Dodel R: Trajectory classes of decline in health-related quality of life in Parkinson’s disease: a pilot study. Value Health 2011; 14: 329–338.
5.
Iddi S, Molenberghs G: A joint marginalized multilevel model for longitudinal outcomes. J Appl Stat 2012; 39: 24132430.
6.
Tsiatis AA, Davidian M: A joint modeling of longitudinal and time-to-event data: an overview. Stat Sin 2004; 14: 809–834.
7.
Luo S, He B: Joint modeling of multivariate longitudinal measurements and survival data with applications to Parkinson’s disease. Stat Methods Med Res 2016; 25: 1346–1358.
8.
Luo S: A Bayesian approach to joint analysis of multivariate longitudinal data and parametric accelerated failure time. Stat Med 2014; 33: 580–594.
9.
Li D, Iddi S, Thompson WK, Donohue MC: Bayesian latent time joint mixed effect models for multicohort longitudinal data. Stat Methods Med Res 2017, DOI: 10. 1177/ 0962280217737566 (Epub ahead of print).
10.
Lewandowski D, Kurowicka D, Joe H: Generating random correlation matrices based on vines and extended onion method. J Multivar Anal 2009; 100: 1989–2001.
11.
Brockmann K, Schulte C, Deuschle C, Hauser A-K, Heger T, Gasser T, Maetzler W, Berg D: Neurodegenerative CSF markers in genetic and sporadic PD: classification and prediction in a longitudinal study. Parkinsonism Relat Disord 2015; 21; 1427–1434.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.